CYTO - Altamira Therapeutics Ltd.
NASDAQ
->
Healthcare
->
Biotechnology
Hamilton,
Bermuda
Type: Equity
CYTO price evolution
CYTO
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.12 | $0.07 | $0.79 | $0.76 |
| Inventory | $0.33 | $0.27 | $0.01 | |
| Total current assets | $0.52 | $1.22 | $1.73 | $1.77 |
| Long term investments | ||||
| Property, plant & equipment | $0.42 | $0.08 | $0.39 | $0.45 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $8.07 | $7.69 | $6.2 | $6.3 |
| Current liabilities | ||||
| Accounts payable | $0.53 | $0.44 | $1.96 | $4.91 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.23 | $0.89 | $5.37 | $12.88 |
| Long term debt | $0.3 | $0.93 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1.75 | $1.24 | $8.03 | $14.62 |
| Shareholders' equity | ||||
| Retained earnings | $6.31 | -$18.05 | -$19.85 | -$201.43 |
| Other shareholder equity | $4.4 | $0.87 | $0.26 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.62 | $0.02 | $0.98 | $12.01 |
| Short term investments | ||||
| Net receivables | $0.07 | $0.76 | $0.94 | $0.09 |
| Inventory | $0.01 | $0.84 | $0 | |
| Total current assets | $1.22 | $1.77 | $3.76 | $12.39 |
| Long term investments | ||||
| Property, plant & equipment | $0.08 | $0.45 | $0.56 | $0.05 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.79 | |||
| Total investments | ||||
| Total assets | $7.69 | $6.3 | $18.84 | $22.18 |
| Current liabilities | ||||
| Accounts payable | $0.41 | $4.77 | $3.54 | $0.81 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.89 | $12.88 | $4.86 | $3.23 |
| Long term debt | ||||
| Total noncurrent liabilities | $1.07 | |||
| Total debt | ||||
| Total liabilities | $1.24 | $14.62 | $6.13 | $4.3 |
| Shareholders' equity | ||||
| Retained earnings | -$18.05 | -$201.43 | -$176.02 | -$171.33 |
| Other shareholder equity | $4.4 | $0.26 | $0.06 | $0.07 |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.06 | $0.31 | ||
| Cost of revenue | ||||
| Gross Profit | $0.09 | -$0.09 | -$0.21 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $3.92 | -$3.35 | $3.44 | $25 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.13 | $0.01 | -$0.01 | |
| Interest expense | -$0.42 | $0.82 | -$0.87 | -$0.41 |
| Net income | ||||
| Net income | -$4.34 | $4.33 | -$5.94 | -$26.53 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.19 | $0.31 | $0.06 | |
| Cost of revenue | ||||
| Gross Profit | -$0.02 | -$0.21 | -$2.18 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1.98 | $12.6 | $13.39 | $5.63 |
| Operating income | -$5.63 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.12 | -$0.01 | $0.02 | -$0.02 |
| Interest expense | -$0.16 | -$0.41 | -$0.27 | $0.14 |
| Net income | ||||
| Net income | -$2.12 | -$26.53 | -$17.39 | -$8.75 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0 | $0 | $0 | -$2.14 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $2.51 | $1.19 | $8.41 | $9.83 |
| Effect of exchange rate | $0.02 | -$0 | $0.06 | $0.02 |
| Change in cash and equivalents | -$0.67 | $0.58 | $0.04 | -$0.97 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$8.75 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$5.17 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0 | -$2.14 | -$3.51 | -$2.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.19 | $9.83 | $6.61 | $18.09 |
| Effect of exchange rate | -$0 | $0.02 | $0.29 | $0.08 |
| Change in cash and equivalents | $0.58 | -$0.97 | -$10.28 | $10.53 |
News
Fundamentals
| Market cap | $801.16K |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.67M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$32.48M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.02 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$12.16 |
|---|---|
| ROA | -459.59% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.43 |
| Quick ratio | N/A |